Inactive Instrument

News Cyclacel Pharmaceuticals Inc Nasdaq

Equities

US23254L3069

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 01	Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer	CI
Mar. 19	Transcript : Cyclacel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cyclacel Pharmaceuticals : April 2024 Corporate Presentation	Apr. 02	PU
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer	Apr. 01	CI
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 20	AQ
Transcript : Cyclacel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024	Mar. 19
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000	Mar. 19	MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be presented at the American Association for Cancer Research Annual Meeting 2024	Mar. 08	AQ
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit	Mar. 07	AQ
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO and Investor Conference	Feb. 21	AQ
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer	Jan. 31	AQ
Cyclacel Pharmaceuticals, Inc. Announces Board Changes	Jan. 30	CI
Cyclacel Pharmaceuticals, Inc. Announces Executive Changes	Jan. 30	CI
Top Premarket Gainers	Jan. 08	MT
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024	Jan. 03	AQ
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $0.026374 million in funding	Dec. 21	CI
North American Morning Briefing : S&P 500 Futures -2-	Dec. 20	DJ
Brookline Capital Downgrades Cyclacel Pharmaceuticals to Hold From Buy	Dec. 19	MT
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions	Dec. 18	CI
Reverse Split: 1 of 15	Dec. 17	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cyclacel Pharmaceuticals Inc Nasdaq

Equities

US23254L3069

Summary

Filters